Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 65 Sarcoma 40 Neoplasm Metastasis 22 Neoplasms 20 Ovarian Neoplasms 17 Breast Neoplasms 17 Carcinoma, Non-Small-Cell Lung 15 Recurrence 7 Leiomyosarcoma 7 Kidney Neoplasms 7 Melanoma 6 Liposarcoma 6 Hemangiosarcoma 6 Glioblastoma 6 Fallopian Tube Neoplasms 6 Thyroid Neoplasms 5 Prostatic Neoplasms 5 Neurofibrosarcoma 5 Lung Neoplasms 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Sarcoma, Synovial 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Histiocytoma, Malignant Fibrous 4 Dermatofibrosarcoma 4 Clear-cell metastatic renal cell carcinoma 4 Chondrosarcoma, Extraskeletal Myxoid 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × pazopanib × Clear all

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡